Methylphenidate IR Dosing
Start methylphenidate immediate-release at 5 mg twice daily (after breakfast and lunch) for children and adolescents, and 5 mg 2-3 times daily for adults, then titrate upward in weekly increments of 5-10 mg per dose until symptoms are controlled or side effects emerge, with a maximum total daily dose of 60 mg. 1, 2
Starting Doses by Age Group
Children and Adolescents (6 years and older)
- Initial dose: 5 mg twice daily (morning after breakfast, noon after lunch) 1, 2
- Given 30-45 minutes before meals for optimal absorption 2
- A third afternoon dose may be added to cover homework and social activities 1
Adults
- Initial dose: 5 mg 2-3 times daily, 30-45 minutes before meals 1
- For those with sleep problems, take the last dose before 6 PM 2
Special Population: Children <25 kg
- Use extra caution with dose escalation
- Single doses should generally not exceed 15 mg 1
- Maximum total daily dose during titration may be limited to 35 mg 1
Titration Schedule
Standard approach: Increase by 5-10 mg per dose weekly if symptom control is inadequate 1
Alternative "forced titration" approach: Trial all four dose levels (5,10,15,20 mg) with each dose lasting 1 week, then select the dose with best efficacy and fewest side effects 1. This method ensures you don't miss a higher dose that might yield additional improvement.
Practical Titration Timeline
- Week 1: 5 mg twice daily
- Week 2: 10 mg twice daily
- Week 3: (skip for children <20 kg)
- Week 4: 15 mg twice daily
- Week 4+: 20 mg twice daily if needed 1
Contact patients weekly by phone during titration to assess response and side effects 1
Maximum Doses
- PDR maximum: 60 mg total daily dose 1
- Expert consensus upper limit: 25 mg per single dose when given multiple times daily 1
- Adults may occasionally require: Up to 1.0 mg/kg/day or 65 mg total daily (to cover longer waking hours), but this requires clear documentation that lower doses were inadequate and higher doses cause no significant side effects 1
Critical caveat: If the top recommended dose doesn't help, more is not necessarily better—consider switching stimulants or adding psychosocial interventions rather than exceeding maximum doses 1
Monitoring Requirements
Before Starting Treatment
- Physical examination with baseline vital signs (blood pressure, pulse, height, weight) 1
- Document prior treatments and assess for contraindications 1
- Screen adolescents for substance use 3
- Assess family history of tics/Tourette's syndrome 1
During Titration (Weeks 1-4)
- Weekly contact (visit or phone) 1
- Obtain parent and teacher ADHD rating scales at each dose change 1
- Systematically assess side effects: insomnia, anorexia, headaches, tics, irritability 1
- Weigh patient at each visit 1
Maintenance Phase
- Monthly visits until symptoms stabilized 1
- Children: Annual vital signs during routine physical 1
- Adults: Quarterly blood pressure and pulse checks 1
Key Clinical Pitfalls
Duration of action: Immediate-release methylphenidate lasts only 3-4 hours 4, 5, necessitating 2-3 times daily dosing. Plan timing carefully to cover school, homework, and social activities without causing insomnia.
Individual variability: Response is highly variable and not predicted by weight or plasma concentrations 4, 5. Dose must be titrated individually based on clinical response, not calculated by body weight.
Timing matters: Behavioral effects peak when plasma concentrations are rising (1-3 hours post-dose), not at steady state 4. This explains why timing relative to meals and activities is crucial.
Rebound symptoms: As each dose wears off, some patients experience symptom rebound or irritability. This may require adjusting dose timing or considering extended-release formulations for maintenance.
Diversion risk in adolescents: Monitor prescription refill patterns and consider nonstimulant alternatives if diversion is suspected 3
The evidence base for these recommendations comes primarily from the 2002 American Academy of Child and Adolescent Psychiatry practice parameter 1, which provides the most comprehensive algorithmic guidance for methylphenidate dosing, supplemented by FDA labeling 2 and recent pharmacokinetic research 4, 5. While this guideline is from 2002, it remains the most detailed evidence-based dosing algorithm available and aligns with current FDA labeling.